Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China
This article was originally published in PharmAsia News
Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.
You may also be interested in...
The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company
Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.